Skip to Main Content

Paper Details

Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
1
2023
Cabozantinib, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic RCC, PD-1, Patients, T, T-effector cell populations, avelumab, cabozantinib, diarrhea, fatigue, hand-foot syndrome, human, human IgG1 monoclonal antibody, mRCC, maculopapular rash, mccRCC, metastatic clear cell renal cell carcinoma, nephritis, patient, patients, programmed death-ligand 1 protein, regulatory, regulatory T cells, tyrosine, tyrosine kinase
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
  • 1 - 1

Datasets

Release 1.2